The cell therapy industry is undergoing a natural evolution from scientific curiosity into a commercially and clinically attractive opportunity (1). This evolution is by no means complete, and growing evidence suggests that its progression is driving significant developments in cell therapy bioprocessing — notably, convergence.
|Number of pages||8|
|Specialist publication||BioProcess International|
|Publication status||Published - 1 Mar 2014|